DIABETIC MACULAR EDEMA (DME)
Clinical trials for DIABETIC MACULAR EDEMA (DME) explained in plain language.
Never miss a new study
Get alerted when new DIABETIC MACULAR EDEMA (DME) trials appear
Sign up with your email to follow new studies for DIABETIC MACULAR EDEMA (DME), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye drug could mean fewer shots for Diabetes-Related vision loss
Disease control Recruiting nowThis study tests a new medicine, EYP-1901, given as an eye injection to people with diabetic macular edema (DME), a condition that causes blurry vision in people with diabetes. The goal is to see if EYP-1901 works as well as the standard treatment (aflibercept) but with fewer inj…
Matched conditions: DIABETIC MACULAR EDEMA (DME)
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New eye drug could cut injection frequency for Diabetes-Related vision loss
Disease control Recruiting nowThis phase 3 trial tests EYP-1901, a new eye injection, against the standard treatment aflibercept for diabetic macular edema (DME), a condition that causes vision loss in people with diabetes. The study will enroll 240 participants and compare how well each drug improves vision …
Matched conditions: DIABETIC MACULAR EDEMA (DME)
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for diabetes-related vision loss: experimental drug faces final test
Disease control Recruiting nowThis study tests a new eye medication called BAT5906 against an approved drug (Lucentis) for people with diabetic macular edema, a condition that causes vision loss in diabetes. About 406 adults with type 1 or type 2 diabetes will receive injections into the eye and be followed f…
Matched conditions: DIABETIC MACULAR EDEMA (DME)
Phase: PHASE3 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Gene therapy injection aims to ease diabetic eye swelling
Disease control Recruiting nowThis early-phase study tests a gene therapy called LX111 for diabetic macular edema (DME), a condition that causes vision loss due to swelling in the retina. About 32 adults with DME will receive a single injection into the eye. The main goals are to check safety and see if it he…
Matched conditions: DIABETIC MACULAR EDEMA (DME)
Phase: EARLY_PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Eye scan showdown: faricimab vs ranibizumab in diabetic retinopathy
Knowledge-focused Recruiting nowThis study compares two eye injections—faricimab and a biosimilar version of ranibizumab—in 100 adults with diabetic retinopathy. Researchers will use eye scans (OCT and OCT angiography) to see which drug leads to better early changes in the retina after three monthly doses. The …
Matched conditions: DIABETIC MACULAR EDEMA (DME)
Phase: NA • Sponsor: Osijek University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC